TITLE

The efficacy and tolerability of combined antidepressant treatment in different depressive subgroups

AUTHOR(S)
O'Brien, Sinead; McKeon, Patrick; O'Regan, Myra; O'Brien, S; McKeon, P; O'Regan, M
PUB. DATE
March 1993
SOURCE
British Journal of Psychiatry;Mar93, Vol. 162, p363
SOURCE TYPE
Academic Journal
DOC. TYPE
journal article
ABSTRACT
Eighty patients admitted to hospital with major depression were randomly allocated to six weeks of treatment with tranylcypromine, amitriptyline, or tranylcypromine and amitriptyline in combination, in a double-blind study. Scores on the HRSD improved significantly in all three groups, but there were no differences between the three groups. Patients on tranylcypromine and amitriptyline combined improved more according to their self-ratings after six weeks, and response was earlier as measured by a clinical global improvement scale. Those with endogenous depression improved more than those with neurotic depression, irrespective of treatment group. Combined treatment was less well tolerated than single treatments and gave rise to more side-effects, although there was no serious toxicity. Orthostatic hypotension was observed more frequently in patients on combined treatment. This group also experienced a significant increase in weight and prolongation of the P-R interval on ECG.
ACCESSION #
24992953

 

Related Articles

  • Safety and Efficacy of Oral Escitalopram as Continuation Treatment of Intravenous Citalopram in Patients with Major Depressive Disorder. Schmitt, Laurent; Tonnoir, Brigitte; Arbus, Christophe // Neuropsychobiology;2006, Vol. 54 Issue 4, p201 

    The objective of this open-label, multicentre study was to evaluate the safety and efficacy of treatment with escitalopram (10 or 20 mg/day) for 6 weeks following a switch from intravenous citalopram treatment (20 or 40 mg/day) in patients presenting with a major depressive episode. A total of...

  • Antidepressant effect of lithium in patients with systemic lupus erythematosus and cerebral infarction, treated with corticosteroid. Terao, Takeshi; Mizuki, Tunetaka; Ohji, Taro; Abe, Kazuhiko; Terao, T; Mizuki, T; Ohji, T; Abe, K // British Journal of Psychiatry;Jan94, Vol. 164, p109 

    Two depressive patients with systemic lupus erythematosus (SLE) and cerebral infarction, while being treated with corticosteroid, are described. In both cases, lithium was remarkably effective and no severe side-effects occurred. These findings suggest that lithium can be a useful antidepressant...

  • Amitriptyline.  // AHFS Consumer Medication Information;Aug2020, p1 

    Amitriptyline is used to treat symptoms of depression. Amitriptyline is in a class of medications called tricyclic antidepressants. It works by increasing the amounts of certain natural substances in the brain that are needed to maintain mental balance.

  • A I)ouble-Blind Out-Patient Trial of Indalpine vs Mianserin. Naylor, G. J.; Martin, B. // British Journal of Psychiatry;Sep85, Vol. 147, p306 

    Indalpine 150 mg per day and mianserin 60 mg per day were compared in a double-blind study of 65 depressed out-patients: 52 patients completed the 4-week trial. At the end of four weeks there was no significant difference in antidepressant effect between the two drugs; but in the first two...

  • The effect of forewarning on the occurrence of side-effects and discontinuance of medication in patients on amitriptyline. Myers, E. D.; Calvert, E. J. // British Journal of Psychiatry;Apr73, Vol. 122 Issue 569, p461 

    The article discusses the study on the impact of prevising patients taking amitriptyline on its side-effects. It is believed that psychological factors are significant in identifying the harmful or good effects of drugs. In an amitriptyline trial, patients were asked to note down their...

  • Recent Progress in Pharmacological and Non-Pharmacological Treatment Options of Major Depression. Baghai, Thomas C.; Moller, Hans-Jurgen; Rupprecht, Rainer // Current Pharmaceutical Design;Feb2006, Vol. 12 Issue 4, p503 

    In spite of recent progress in the pharmacotherapy of depression major issues are still unresolved. These include the non-response rate of approximately 30% to conventional antidepressant pharmacotherapy, side effects of available antidepressants and the latency of several weeks until clinical...

  • Clinical assessment and performance tasks in depression: a comparison of amitriptyline and trazodone. Botros, W. A.; Ankier, S. I.; Priest, A. G.; Mcmanus, I. C.; Steinert, J.; Samir, Z. Y.; Priest, R G // British Journal of Psychiatry;Oct89, Vol. 155, p479 

    Depression, anxiety and psychomotor performance were assessed in 20 depressed patients during double-blind treatment with amitriptyline or trazodone. There was no difference in onset of antidepressant or anxiolytic action. No decrement or improvement on computerised tasks was found. Dry mouth...

  • Milnacipran.  // Reactions Weekly;3/17/2007, Issue 1143, p19 

    This article presents a case study of piloerection that developed in a 40-year-old woman during treatment with milnacipran for depression. It discusses the clinical history of the patient and the findings of the physical and laboratory examinations conducted on the patient. It details the...

  • Bupropion.  // Reactions Weekly;6/6/2009, Issue 1255, p11 

    The article describes a case of psychosis in a 36-year-old female patient induced by bupropion treatment for a depressive disorder. Information is given on the medical history of the patient. It explores the symptoms experienced by the patient, which include persecutory and referential delusions...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics